A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 6, 2009, Pages 913-918

  Salemi, S ^a   Yousefi, S ^a   Simon, D ^a   Schmid, I ^a   Moretti, L ^b   Scapozza, L ^b   Simon, Hans Uwe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Chronic eosinophilic leukemia; Eosinophils; Genetics; Hypereosinophilia; Hypereosinophilic syndrome; Imatinib resistance; Molecular modeling

Indexed keywords

FIP 1 LIKE 1 PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA; GENE PRODUCT; IMATINIB; PHOSPHOTRANSFERASE; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BINDING; ENZYME CONFORMATION; EOSINOPHILIC LEUKEMIA; GENE FUSION; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BENZENESULFONATES; CHRONIC DISEASE; DRUG RESISTANCE; HUMANS; HYPEREOSINOPHILIC SYNDROME; MOLECULAR SEQUENCE DATA; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 65549100146     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2009.01943.x     Document Type: Article

References (30)

1. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol 2007 119 : 1291 1300. (Pubitemid 46855844)
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003 348 : 1201 1214. (Pubitemid 36359296)
3. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002 359 : 1577 1578. (Pubitemid 34621126)
4. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004 103 : 473 478. (Pubitemid 38140075)
5. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Haematol 2004 77 : 82 85. (Pubitemid 39108803)
6. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003 100 : 7830 7835. (Pubitemid 36760055)
7. von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J. Myeloid blast crisis evolving during imatinib treatment of a FIP1L1-PDGFRalpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005 19 : 286 287. (Pubitemid 40220595)
8. Ohnishi H, Kandabashi K, Maeda Y, Kawamura M, Watanabe T. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T674I mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006 134 : 547 549. (Pubitemid 44141723)
9. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 293 : 876 880. (Pubitemid 32743979)
10. Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor α-positive eosinophilic leukemia. J Allergy Clin Immunol 2008 121 : 1054 1056.
11. Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 2008 14 : 949 953.
12. Vassina EM, Yousefi S, Simon D, Zwicky C, Conus S, Simon HU. XcIAP-2 and survivin contribute to cytokine-mediated delayed eosinophil apoptosis. Eur J Immunol 2006 36 : 1975 1984. (Pubitemid 44089062)
13. Altznauer F, Martinelli S, Yousefi S, Thürig C, Schmid I, Conway EM et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J Exp Med 2004 199 : 1343 1354. (Pubitemid 38685726)
14. Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L et al. Characterization of compound 584, an Abl kinase inhibitor with lasting effects. Haematologica 2008 93 : 653 661.
15. Lierman E, Folens C, Stover EH, Mentens N, van Miegroet H, Scheers W et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant. Blood 2006 108 : 1374 1376. (Pubitemid 44232039)
16. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004 279 : 31655 31663. (Pubitemid 39037836)
17. Mol CD, Lim KB, Sridhar V, Zou H, Chien EY, Sang BC et al. Structure of a c-Kit product complex reveals the basis for kinase transactivation. J Biol Chem 2003 278 : 31461 31464. (Pubitemid 37048320)
18. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993 234 : 779 815. (Pubitemid 24007801)
19. Van der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. Gromacs: fast, flexible, and free. J Comput Chem 2005 26 : 1701 1718. (Pubitemid 43076182)
20. Lehtonen JV, Still DJ, Rantanen VV, Ekholm J, Björklund D, Iftikhar Z et al. Bodil: a molecular modeling environment for structure function-analysis and drug design. J Comput Aided Mol Des 2004 18 : 401 419. (Pubitemid 40069138)
21. Beitz E. Texshade: shading and labeling of multiple sequence alignments using latex2 epsilon. Bioinformatics 2000 16 : 135 139. (Pubitemid 30248590)
22. DeLano WL. The pymol molecular graphics system. Available at: http://www.pymol.org/, 2003.
23. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 : 2129 2139. (Pubitemid 38637993)
24. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002 62 : 4236 4243.
25. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004 116 : 855 867. (Pubitemid 38410730)
26. Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004 13 : 169 178. (Pubitemid 38183264)
27. Walter M, Lucet IS, Patel O, Broughton SE, Bamert R, Williams NK et al. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 2007 367 : 839 847. (Pubitemid 46330380)
28. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003 112 : 831 843. (Pubitemid 36378885)
29. Gambacorti-Passerini C, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Ph+ leukemias. Lancet Oncol 2003 4 : 75 85.
30. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH III. et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006 66 : 1007 1013. (Pubitemid 43168337)